This site is intended for healthcare professionals

Diabetes and endocrinology

In this episode, Professor Pratik Choudhary summarises the findings from the InRange study, the first randomised, Phase 4 study to use Time in Range as the primary endpoint to compare second-generation basal insulin analogues, Toujeo (insulin glargine 300 U/mL) and insulin degludec 100 U/mL, in people with type 1 diabetes.¹
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris fermentum purus id arcu facilisis pulvinar. In hac habitasse platea dictumst. Etiam at hendrerit mauris. Aliquam vehicula nibh eget sem lacinia tincidunt. Aliquam in malesuada leo. Nullam at elit id purus imperdiet scelerisque. Praesent non urna sem. Nunc tortor ante, finibus.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris fermentum purus id arcu facilisis pulvinar. In hac habitasse platea dictumst. Etiam at hendrerit mauris. Aliquam vehicula nibh eget sem lacinia tincidunt. Aliquam in malesuada leo. Nullam at elit id purus imperdiet scelerisque. Praesent non urna sem. Nunc tortor ante, finibus.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris fermentum purus id arcu facilisis pulvinar. In hac habitasse platea dictumst. Etiam at hendrerit mauris. Aliquam vehicula nibh eget sem lacinia tincidunt. Aliquam in malesuada leo. Nullam at elit id purus imperdiet scelerisque. Praesent non urna sem. Nunc tortor ante, finibus.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris fermentum purus id arcu facilisis pulvinar. In hac habitasse platea dictumst. Etiam at hendrerit mauris. Aliquam vehicula nibh eget sem lacinia tincidunt. Aliquam in malesuada leo. Nullam at elit id purus imperdiet scelerisque. Praesent non urna sem. Nunc tortor ante, finibus.

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

GPnotebook_podcast_white-text

Would you like to receive updates about new podcast episodes by email? (You can unsubscribe at any time)